Evaluating the Effect of Sorafenib on Gd-EOB-DTPA-mediated Contrast Enhancement: An Experimental Study using DCE-MRI.

IF 2.5 4区医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Molecular Imaging and Biology Pub Date : 2026-06-01 Epub Date: 2026-05-13 DOI:10.1007/s11307-026-02109-5

Yeon Ji Chae, Do-Wan Lee, Chul-Woong Woo, Yu Sub Sung, Jung-Hyun Choi, Eunyoung Tak, Chang Hoon Ha, Jin Kyung Roh, In-Jeoung Baek, Chan-Gi Pack, Hwon Heo, Kyung Won Kim, Jeong Kon Kim, Yoonseok Choi, Dong-Cheol Woo

{"title":"Evaluating the Effect of Sorafenib on Gd-EOB-DTPA-mediated Contrast Enhancement: An Experimental Study using DCE-MRI.","authors":"Yeon Ji Chae, Do-Wan Lee, Chul-Woong Woo, Yu Sub Sung, Jung-Hyun Choi, Eunyoung Tak, Chang Hoon Ha, Jin Kyung Roh, In-Jeoung Baek, Chan-Gi Pack, Hwon Heo, Kyung Won Kim, Jeong Kon Kim, Yoonseok Choi, Dong-Cheol Woo","doi":"10.1007/s11307-026-02109-5","DOIUrl":null,"url":null,"abstract":"Purpose: Despite the potential impact of sorafenib on gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-mediated contrast enhancements, attempts to assess these effects are rare. This study aimed to investigate the interaction between Sorafenib and Gd-EOB-DTPA by quantifying the T1 and T2 relaxation times and the relative enhancement rates (RERs) of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in the liver.Procedures: The effects on contrast enhancement were assessed using MRI with Chang liver cells and SD rats. MR phantom images were obtained after treating cells with varying dosages of Gd-EOB-DTPA (5, 10 mM) and sorafenib (10, 30 μM) to evaluate MR relaxivities. For the animal study, DCE-MRI was performed following intravenous administration of 25 µmol/kg Gd-EOB-DTPA and two different doses of sorafenib (10, 30 mg/kg). RER was analyzed to evaluate sorafenib's effects on Gd-EOB-DTPA uptake in the liver.Results: Phantom experiments demonstrated alterations in T1 and T2 values, with a tendency towards shortening disrupted by the addition of sorafenib to Gd-EOB-DTPA-treated Chang liver cells. The RERs of DCE-MRI in the liver exhibited a dose-dependent decrease following sorafenib administration, with recovery observed after 4 h.Conclusions: Our results provide quantitative information on sorafenib-mediated interference with Gd-EOB-DTPA-induced contrast enhancement and offer experimental evidence suggesting the possibility of drug-drug interactions between sorafenib and Gd-EOB-DTPA. Although further research is needed to fully elucidate the impact of these interactions, caution is warranted when using these two agents concurrently for liver MRI.","PeriodicalId":18760,"journal":{"name":"Molecular Imaging and Biology","volume":" ","pages":"531-538"},"PeriodicalIF":2.5000,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Imaging and Biology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11307-026-02109-5","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/5/13 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Despite the potential impact of sorafenib on gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-mediated contrast enhancements, attempts to assess these effects are rare. This study aimed to investigate the interaction between Sorafenib and Gd-EOB-DTPA by quantifying the T1 and T2 relaxation times and the relative enhancement rates (RERs) of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in the liver.

Procedures: The effects on contrast enhancement were assessed using MRI with Chang liver cells and SD rats. MR phantom images were obtained after treating cells with varying dosages of Gd-EOB-DTPA (5, 10 mM) and sorafenib (10, 30 μM) to evaluate MR relaxivities. For the animal study, DCE-MRI was performed following intravenous administration of 25 µmol/kg Gd-EOB-DTPA and two different doses of sorafenib (10, 30 mg/kg). RER was analyzed to evaluate sorafenib's effects on Gd-EOB-DTPA uptake in the liver.

Results: Phantom experiments demonstrated alterations in T1 and T2 values, with a tendency towards shortening disrupted by the addition of sorafenib to Gd-EOB-DTPA-treated Chang liver cells. The RERs of DCE-MRI in the liver exhibited a dose-dependent decrease following sorafenib administration, with recovery observed after 4 h.

Conclusions: Our results provide quantitative information on sorafenib-mediated interference with Gd-EOB-DTPA-induced contrast enhancement and offer experimental evidence suggesting the possibility of drug-drug interactions between sorafenib and Gd-EOB-DTPA. Although further research is needed to fully elucidate the impact of these interactions, caution is warranted when using these two agents concurrently for liver MRI.

查看原文本刊更多论文

评价索拉非尼对gd - eob - dtpa介导的对比度增强的影响：DCE-MRI的实验研究。

目的：尽管索拉非尼对钆-乙氧基苄基-二乙烯三胺五乙酸（Gd-EOB-DTPA）介导的造影剂增强有潜在影响，但评估这些影响的尝试很少。本研究旨在通过量化肝脏动态磁共振成像（DCE-MRI） T1、T2弛豫时间和相对增强率（RERs），探讨索拉非尼与Gd-EOB-DTPA之间的相互作用。方法：采用MRI对Chang肝细胞和SD大鼠进行对比增强效果评估。用不同剂量的Gd-EOB-DTPA（5、10 mM）和索拉非尼（10、30 μM）处理细胞后，获得MR幻像，以评估MR松弛度。在动物实验中，在静脉给药25µmol/kg Gd-EOB-DTPA和两种不同剂量的索拉非尼（10、30 mg/kg）后进行DCE-MRI。分析RER以评估索拉非尼对肝脏中Gd-EOB-DTPA摄取的影响。结果：幻影实验显示T1和T2值的改变，在gd - eob - dtpa处理的Chang肝细胞中添加索拉非尼，有缩短的趋势。索拉非尼给药后，肝脏DCE-MRI的rres呈剂量依赖性下降，4 h后恢复。结论：我们的研究结果提供了索拉非尼介导的Gd-EOB-DTPA造影剂增强干扰的定量信息，并提供了索拉非尼与Gd-EOB-DTPA之间可能存在药物-药物相互作用的实验证据。虽然需要进一步的研究来充分阐明这些相互作用的影响，但在同时使用这两种药物进行肝脏MRI时需要谨慎。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular Imaging and Biology 医学-核医学

CiteScore

6.90

自引率

3.20%

发文量

审稿时长

3 months

期刊介绍： Molecular Imaging and Biology (MIB) invites original contributions (research articles, review articles, commentaries, etc.) on the utilization of molecular imaging (i.e., nuclear imaging, optical imaging, autoradiography and pathology, MRI, MPI, ultrasound imaging, radiomics/genomics etc.) to investigate questions related to biology and health. The objective of MIB is to provide a forum to the discovery of molecular mechanisms of disease through the use of imaging techniques. We aim to investigate the biological nature of disease in patients and establish new molecular imaging diagnostic and therapy procedures. Some areas that are covered are: Preclinical and clinical imaging of macromolecular targets (e.g., genes, receptors, enzymes) involved in significant biological processes. The design, characterization, and study of new molecular imaging probes and contrast agents for the functional interrogation of macromolecular targets. Development and evaluation of imaging systems including instrumentation, image reconstruction algorithms, image analysis, and display. Development of molecular assay approaches leading to quantification of the biological information obtained in molecular imaging. Study of in vivo animal models of disease for the development of new molecular diagnostics and therapeutics. Extension of in vitro and in vivo discoveries using disease models, into well designed clinical research investigations. Clinical molecular imaging involving clinical investigations, clinical trials and medical management or cost-effectiveness studies.